Morbimortality and determinants of reperfusion in ischemic stroke
- PMID: 38126448
- PMCID: PMC10729669
- DOI: 10.1590/1806-9282.20230472
Morbimortality and determinants of reperfusion in ischemic stroke
Abstract
Background: Cerebrovascular accident (or stroke) and ischemic heart disease are the the major causes of death in the world. It is estimated that about 85% of strokes are ischemic in origin. Reperfusion therapy in the acute phase of ischemic stroke with a recombinant human tissue plasminogen activator is effective, but some factors influence the success of this treatment.
Objective: The aim of this study was to evaluate clinical aspects and possible determinants for reperfusion after venous thrombolysis.
Methods: This is a retrospective, cross-sectional, observational study based on a review of hospital records of inpatients diagnosed with ischemic stroke treated with intravenous thrombolysis, the main outcome being reperfusion or not.
Results: Data from this study revealed a predominance of females in the group of reperfused patients and males in the non-reperfused group, both maintaining moderate severity on the National Institutes of Health Stroke Scale and admission without statistical significance (p>0.18). In addition, the mean admission severity score was 13.2 for the group of reperfused patients and 14.2 for those not reperfused, and the mean ejection fraction of both groups was within normal functionality, with a mean of 0.50 for reperfused patients and 0.62 for non-reperfused patients.
Conclusion: We found an association between successful venous chemical thrombolysis reperfusion and lower mortality in patients with acute stroke.
Conflict of interest statement
Conflicts of interest: the authors declare there is no conflicts of interest.
Similar articles
-
Intravenous thrombolysis for acute ischemic stroke in the 3- to 4·5-hour window--the Malabar experience.Int J Stroke. 2014 Jun;9(4):426-8. doi: 10.1111/ijs.12128. Epub 2013 Aug 26. Int J Stroke. 2014. PMID: 23981667
-
Influence of Penumbral Reperfusion on Clinical Outcome Depends on Baseline Ischemic Core Volume.Stroke. 2017 Oct;48(10):2739-2745. doi: 10.1161/STROKEAHA.117.018587. Epub 2017 Sep 8. Stroke. 2017. PMID: 28887396
-
Tissue at risk of infarction rescued by early reperfusion: a positron emission tomography study in systemic recombinant tissue plasminogen activator thrombolysis of acute stroke.J Cereb Blood Flow Metab. 1998 Dec;18(12):1298-307. doi: 10.1097/00004647-199812000-00004. J Cereb Blood Flow Metab. 1998. PMID: 9850142 Clinical Trial.
-
Repeated intravenous thrombolysis in recurrent ischemic stroke within 3 months: a systematic review.BMC Neurol. 2023 Nov 27;23(1):422. doi: 10.1186/s12883-023-03472-4. BMC Neurol. 2023. PMID: 38012577 Free PMC article.
-
Treatment of Acute Ischemic Stroke.Continuum (Minneap Minn). 2017 Feb;23(1, Cerebrovascular Disease):62-81. doi: 10.1212/CON.0000000000000420. Continuum (Minneap Minn). 2017. PMID: 28157744 Review.
Cited by
-
The reperfusion rates after recombinant human tissue plasminogen activator thrombolysis depend not on a few but on a plethora of influencing factors.Rev Assoc Med Bras (1992). 2024 May 20;70(5):e20240103. doi: 10.1590/1806-9282.20240103. eCollection 2024. Rev Assoc Med Bras (1992). 2024. PMID: 38775518 Free PMC article. No abstract available.
-
Amentoflavone for treating cardiocerebrovascular diseases and neurological disorders.Front Pharmacol. 2024 Nov 18;15:1406510. doi: 10.3389/fphar.2024.1406510. eCollection 2024. Front Pharmacol. 2024. PMID: 39624841 Free PMC article. Review.
References
-
- WHO . The top 10 causes of death. 2018. Available from: http://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death .
-
- Oliveira J, Filho, Martins SCO, Pontes OM, Neto, Longo A, Evaristo EF, Carvalho JJF, et al. Stroke treatment: guidelines. Diretrizes para tratamento do acidente vascular isquêmico – parte I. Arq NeuroPsiquiatr. [online] 2012;70(4):621–629. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical